New pill aims to slow Alzheimer's: phase 2 trial underway
NCT ID NCT07252440
First seen Dec 24, 2025 · Last updated Jun 19, 2026 · Updated 34 times
Summary
This Phase 2 trial tests whether TTYP01 tablets can slow cognitive decline in people with early Alzheimer's disease. About 180 participants aged 60-85 with mild cognitive impairment or mild dementia will receive either a low dose, high dose, or placebo for 78 weeks. Researchers will measure changes in memory tests, brain scans, and blood markers to see if the drug is safe and effective.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EARLY ALZHEIMER'S DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Daping Hospital.
RECRUITINGChongqing, Chongqing Municipality, 400042, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
TTYP01 tablets
What this could lead to
If successful, TTYP01 could slow cognitive decline in early Alzheimer's, offering a new treatment option for patients.
What could go wrong
This is an early Phase 2 trial with only 180 participants. The drug may not show benefit over placebo, and side effects are still being studied.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.